BMS cancer med could earn $500M

Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as a stand-alone treatment for patients who've failed other chemotherapy and for use in tandem with Roche's Xeloda in patients whose cancer has spread. A treatment course of Ixempra is expected to cost $18,000 to $23,000.

- see the BMS release
- check out the report from The Star-Ledger
- read the article from PharmaTimes

Related Articles:
BMS pays $505M for Adnexus. Report
Better times ahead for BMS? Report
Cornelius get big payday for BMS temp job. Report

Read more on: Bristol-Myers Squibb

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.